» Articles » PMID: 27600227

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer

Overview
Date 2016 Sep 8
PMID 27600227
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this applies to the 7000 new cases diagnosed yearly in the UK. Stratification of patients with this heterogeneous disease, based on active molecular pathways, would aid a targeted treatment improving the prognosis for many cases. While hundreds of genes have been associated with ovarian cancer, few have yet been verified by peer research for clinical significance. Here, a meta-analysis approach was applied to two carefully selected gene expression microarray datasets. Artificial neural networks, Cox univariate survival analyses and T-tests identified genes whose expression was consistently and significantly associated with patient survival. The rigor of this experimental design increases confidence in the genes found to be of interest. A list of 56 genes were distilled from a potential 37,000 to be significantly related to survival in both datasets with a FDR of 1.39859 × 10(-11), the identities of which both verify genes already implicated with this disease and provide novel genes and pathways to pursue. Further investigation and validation of these may lead to clinical insights and have potential to predict a patient's response to treatment or be used as a novel target for therapy.

Citing Articles

Novel markers of human ovarian granulosa cell differentiation toward osteoblast lineage: A microarray approach.

Brazert M, Kranc W, Celichowski P, Ozegowska K, Budna-Tukan J, Jeseta M Mol Med Rep. 2019; 20(5):4403-4414.

PMID: 31702034 PMC: 6797957. DOI: 10.3892/mmr.2019.10709.

References
1.
Chu C, Rubin S . Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 2005; 20(2):307-20. DOI: 10.1016/j.bpobgyn.2005.10.012. View

2.
Miller D, Blessing J, Krasner C, Mannel R, Hanjani P, Pearl M . Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009; 27(16):2686-91. PMC: 2690393. DOI: 10.1200/JCO.2008.19.2963. View

3.
Jacobs I, Menon U . Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004; 3(4):355-66. DOI: 10.1074/mcp.R400006-MCP200. View

4.
Singh R, Mukhopadhyay K . Survival analysis in clinical trials: Basics and must know areas. Perspect Clin Res. 2011; 2(4):145-8. PMC: 3227332. DOI: 10.4103/2229-3485.86872. View

5.
Allison D, Cui X, Page G, Sabripour M . Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet. 2005; 7(1):55-65. DOI: 10.1038/nrg1749. View